# A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis

> **NCT03969329** · PHASE3 · RECRUITING · sponsor: **Amgen** · enrollment: 24 (estimated)

## Conditions studied

- Secondary Hyperparathyroidism

## Interventions

- **DRUG:** Etelcalcetide

## Key facts

- **NCT ID:** NCT03969329
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-12-20
- **Primary completion:** 2027-06-30
- **Final completion:** 2027-06-30
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03969329

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03969329, "A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT03969329. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*